ARRIVENT BIOPHARMA, INC.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2022 | — | — | $163.4M |
| FY2023 | $11.8M | $163.1M | $150.4M |
| FY2024 | $17.3M | $274.9M | $74.3M |
| FY2025 | $25.9M | $333.2M | $45.5M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2022 | — | — | $163.4M |
| FY2023 | $11.8M | $163.1M | $150.4M |
| FY2024 | $17.3M | $274.9M | $74.3M |
| FY2025 | $25.9M | $333.2M | $45.5M |